DCM
ORKA

Driehaus Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Driehaus Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-308,795
Closed -$5.99M – 470
2024
Q4 		$5.99M Hold
308,795
– – 0.05% 284
2024
Q3 		$7.57M Buy
+308,795
New +$10.7M 0.07% 250

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Driehaus Capital Management's ORKA Position: Q1 2025 in Review

Driehaus Capital Management sold out of Oruka Therapeutics (ORKA) in Q1 2025, closing a stake of 308,795 shares — an estimated $5.99M sold.

Driehaus Capital Management first reported a position in ORKA in Q3 2024 and held it in 2 quarters. The position peaked at $7.57M in Q3 2024. 71 funds tracked by Wall St. Rank hold ORKA as of Q1 2025.

  • Driehaus Capital Management reported no remaining Oruka Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 308,795 Oruka Therapeutics shares in Q1 2025, an estimated $5.99M.
  • Driehaus Capital Management first reported a position in Oruka Therapeutics in Q3 2024 and held it in 2 quarters.
  • Driehaus Capital Management's Oruka Therapeutics position peaked at $7.57M in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2025.

Based on Driehaus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.